CAS 1415925-18-6

GSK2795039

CAS: 1415925-18-6

GSK2795039 reduces ROS, NADPH use, apoptosis, and inhibits NOX2 (pIC50: 6).

Fórmula: C₂₃H₂₆N₆O₂S

Pureza: 95.8% - 97.72%

Cor e Forma: Solid

Peso molecular: 450.56

Ref: TM-T15433

N-(1-Isopropyl-3-(1-Methylindolin-6-Yl)-1H-Pyrrolo[2,3-B]Pyridin-4-Yl)-1-Methyl-1H-Pyrazole-3-Sulfonamide

CAS: 1415925-18-6

N-(1-Isopropyl-3-(1-Methylindolin-6-Yl)-1H-Pyrrolo[2,3-B]Pyridin-4-Yl)-1-Methyl-1H-Pyrazole-3-Sulfonamide

Pureza: 97%

Peso molecular: 450.56g/mol

Ref: 54-OR1023800

GSK2795039

CAS: 1415925-18-6

GSK2795039

Pureza: ≥95%

Peso molecular: 450.56g/mol

Ref: 54-BUP04468

N-(1-Isopropyl-3-(1-methylindolin-6-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)-1-methyl-1H-pyrazole-3-sulfonamide

CAS: 1415925-18-6

Pureza: 97%

Peso molecular: 450.5599976

Ref: 10-F870295

GSK2795039

CAS: 1415925-18-6

GSK2795039 is a molecule that may be a potential therapeutic for hypoxic tumours. GSK2795039 inhibits the activity of an enzyme called dinucleotide phosphate, which is involved in the regulation of reactive oxygen species. This drug shows inhibitory effects on tumor cell proliferation and microenvironment. It also has pharmacokinetic properties that are similar to those of other drugs used for the treatment of cancer, such as postoperative radiotherapy. GSK2795039 was shown to have an inhibitory effect on human liver cells in vitro, and it is thought to be effective against both colorectal cancer and lung cancer.

Fórmula: C₂₃H₂₆N₆O₂S

Pureza: Min. 95%

Peso molecular: 450.56 g/mol

Ref: 3D-QGC92518